CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial and operational results for the fourth quarter and year ended December 31, 2011.
“Idera’s proprietary drug candidates targeting Toll-like Receptors, or TLRs, have advanced to Phase 2 clinical trials in both of our key therapeutic areas of focus: oncology and autoimmune diseases,” said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. “During the second quarter of this year, we anticipate data from a randomized Phase 2 trial of IMO-2055 in combination with Erbitux in patients with second-line squamous cell carcinoma of the head and neck. We also expect to initiate a Phase 2 study of IMO-3100 in patients with psoriasis in the second quarter.”
